Glutamatergic modulatory therapy for Tourette syndrome

Medical Hypotheses

Volumn 74, Issue 5, 2010, Pages 862-867

  Singer, Harvey S ^a   Morris, Christina ^a   Grados, Marco ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPA RECEPTOR; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLYCINE TRANSPORTER; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; RILUZOLE; SARCOSINE;

ADD ON THERAPY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GILLES DE LA TOURETTE SYNDROME; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL DISABILITY; PROTEIN PROTEIN INTERACTION; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA; THALAMOCORTICAL TRACT; TIC; UNSPECIFIED SIDE EFFECT;

CYCLOSERINE; DOPAMINE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; PREFRONTAL CORTEX; RILUZOLE; SYNAPTIC TRANSMISSION; TOURETTE SYNDROME;

EID: 77950918756     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.11.028     Document Type: Article

References (83)

1. The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol 1993;50(10):1013-1016.
2. Kurlan R., McDermott M.P., Deeley C., et al. Prevalence of tics in school children and association with placement in special education. Neurology 2001, 57(8):1383-1388.
3. Robertson M.M. Diagnosing Tourette syndrome: is it a common disorder?. J Psychosom Res 2003, 55(1):3-6.
4. Khalifa N., von Knorring A.L. Prevalence of tic disorders and Tourette syndrome in a Swedish school population. Dev Med Child Neurol 2003, 45(5):315-319.
5. Leckman J.F., Zhang H., Vitale A., et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998, 102(1 Pt. 1):14-19.
6. Bloch M.H., Peterson B.S., Scahill L., et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med 2006, 160(1):65-69.
7. Nieuwenhuys R. The neocortex. An overview of its evolutionary development, structural organization and synaptology. Anat Embryol (Berl) 1994, 190(4):307-337.
8. Clements J.D., Westbrook G.L. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-d-aspartate receptor. Neuron 1991, 7(4):605-613.
9. Sulzer D., Joyce M.P., Lin L., et al. Dopamine neurons make glutamatergic synapses in vitro. J Neurosci 1998, 18(12):4588-4602.
10. Kaneko T., Akiyama H., Nagatsu I., Mizuno N. Immunohistochemical demonstration of glutaminase in catecholaminergic and serotoninergic neurons of rat brain. Brain Res 1990, 507(1):151-154.
11. Mrzljak L., Bergson C., Pappy M., Huff R., Levenson R., Goldman-Rakic P.S. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 1996, 381(6579):245-248.
12. Smiley J.F., Levey A.I., Ciliax B.J., Goldman-Rakic P.S. D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 1994, 91(12):5720-5724.
13. Del Arco A., Mora F. Endogenous dopamine potentiates the effects of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat. Brain Res Bull 2000, 53(3):339-345.
14. Seamans J.K., Gorelova N., Durstewitz D., Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001, 21(10):3628-3638.
15. Gorelova N., Seamans J.K., Yang C.R. Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 2002, 88(6):3150-3166.
16. Yang C.R., Seamans J.K., Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 1999, 21(2):161-194.
17. Seamans J.K., Durstewitz D., Christie B.R., Stevens C.F., Sejnowski T.J. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci USA 2001, 98(1):301-306.
18. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999, 46(10):1388-1395.
19. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000, 48(7):627-640.
20. Jackson M.E., Frost A.S., Moghaddam B. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J Neurochem 2001, 78(4):920-923.
21. Taber M.T., Fibiger H.C. Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J Neurosci 1995, 15(5 Pt. 2):3896-3904.
22. Daly D.A., Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993, 152(1-2):61-64.
23. Morari M., O'Connor W.T., Ungerstedt U., Fuxe K. Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid. Eur J Pharmacol 1994, 256(1):23-30.
24. Levine M.S., Li Z., Cepeda C., Cromwell H.C., Altemus K.L. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 1996, 24(1):65-78.
25. Centonze D., Picconi B., Gubellini P., Bernardi G., Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 2001, 13(6):1071-1077.
26. Nicola S.M., Surmeier J., Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000, 23:185-215.
27. Cepeda C., Levine M.S. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 1998, 20(1):1-18.
28. Cepeda C., Hurst R.S., Altemus K.L., et al. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 2001, 85(2):659-670.
29. Onn S.P., West A.R., Grace A.A. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000, 23(10 Suppl):S48-56.
30. West A.R., Grace A.A. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002, 22(1):294-304.
31. Marti M., Mela F., Bianchi C., Beani L., Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 2002, 83(3):635-644.
32. Singer H.S., Harris K. Circuits to synapses: The pathophysiology of tourette syndrome. Neurobiology of disease 2006, Elsevier Academic Press, Burlington, MA. first ed. S. Gilman (Ed.).
33. Berardelli A., Curra A., Fabbrini G., Gilio F., Manfredi M. Pathophysiology of tics and Tourette syndrome. J Neurol 2003, 250(7):781-787.
34. Hoekstra P.J., Anderson G.M., Limburg P.C., Korf J., Kallenberg C.G., Minderaa R.B. Neurobiology and neuroimmunology of Tourette's syndrome: an update. Cell Mol Life Sci 2004, 61(7-8):886-898.
35. Singer H.S., Minzer K. Neurobiology of Tourette syndrome: concepts of neuroanatomical localization and neurochemical abnormalities. Brain and Development 2003, 25(Suppl.):S70-S84.
36. Castellanos F.X., Giedd J.N., Elia J., et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997, 36(5):589-596.
37. Harris K., Singer H.S. Tic Disorders: Neural Circuits, Neurochemistry, and Neuroimmunology. J Child Neurology 2006, 21:678-689.
38. Singer H.S., Szymanski S., Giuliano J., et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002, 159(8):1329-1336.
39. Wong D.F., Brasic J.R., Singer H.S., et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008, 33(6):1239-1251.
40. Aalto S., Ihalainen J., Hirvonen J., et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005, 182(3):375-383.
41. Minzer K., Lee O., Hong J.J., Singer H.S. Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum. J Neurol Sci 2004, 219(1-2):55-61.
42. Yoon D.Y., Gause C.D., Leckman J.F., Singer H.S. Frontal dopaminergic abnormality in Tourette syndrome: A postmortem analysis. J Neurol Sci 2007, 255(1-2):50-56.
43. Anderson G.M., Pollak E.S., Chatterjee D., Leckman J.F., Riddle M.A., Cohen D.J. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 1992, 58:123-133.
44. Anderson G.M., Pollak E.S., Chatterjee D., Leckman J.F., Riddle M.A., Cohen D.J. Brain monoamines and amino acids in Gilles de la Tourette's syndrome: a preliminary study of subcortical regions. Arch Gen Psychiatry 1992, 49(7):584-586.
45. Barr C.L., Wigg K.G., Pakstis A.J., et al. Genome scan for linkage to Gilles de la Tourette syndrome. Am J Med Genet 1999, 88(4):437-445.
46. Laurin N., Lee J., Ickowicz A., et al. Association study for genes at chromosome 5p13-q11 in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(5):600-605.
47. TSAICG. Genome scan for Tourette disorder in affected-sibling-pair and multigenerational families. Am J Hum Genet 2007;80(2):265-272.
48. Adamczyk A, Gause CD, Sattler R, et al. A functional missense variant in a glutamate transporter, EAAT1, in Tourette syndrome, submitted for publication .
49. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30(9):1735-1740.
50. Arnold P.D., Sicard T., Burroughs E., Richter M.A., Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006, 63(7):769-776.
51. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006, 63(7):778-785.
52. Wang Y., Adamczyk A., Shugart Y.Y., et al. A screen of SLC1A1 for OCD-related alleles. Am J Med Genet B Neuropsychiatr Genet 2009.
53. Nieoullon A., Canolle B., Masmejean F., Guillet B., Pisano P., Lortet S. The neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a major actor at the brain excitatory synapse?. J Neurochem 2006, 98(4):1007-1018.
54. Arnold P.D., Rosenberg D.R., Mundo E., Tharmalingam S., Kennedy J.L., Richter M.A. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004, 174(4):530-538.
55. Arnold P.D., Macmaster F.P., Richter M.A., et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Res 2009, 172(2):136-139.
56. Waxman E.A., Baconguis I., Lynch D.R., Robinson M.B. N-methyl-D-aspartate receptor-dependent regulation of the glutamate transporter excitatory amino acid carrier 1. J Biol Chem 2007, 282(24):17594-17607.
57. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3(1):69-81.
58. Coric V., Taskiran S., Pittenger C., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005, 58(5):424-428.
59. Pittenger C., Krystal J.H., Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry 2005, 66(11):1492-1493.
60. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10(10):808-819.
61. Mathew S.J., Amiel J.M., Coplan J.D., Fitterling H.A., Sackeim H.A., Gorman J.M. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 2005, 162(12):2379-2381.
62. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006, 12(21):2701-2720.
63. Wu J., Tang T., Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett 2006, 407(3):219-223.
64. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007, 17(6):761-767.
65. Coric V., Milanovic S., Wasylink S., Patel P., Malison R., Krystal J.H. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003, 167(2):219-220.
66. Feusner J.D., Kerwin L., Saxena S., Bystritsky A. Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial. Psychopharmacol Bull 2009, 42(1):81-93.
67. Robertson M.M., Trimble M.R., Lees A.J. The psychopathology of the Gilles de la Tourette syndrome. A phenomenological analysis. Br J Psychiatry 1988, 152:383-390.
68. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009, 12(4):468-478.
69. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005, 62(11):1196-1204.
70. Lane H.Y., Huang C.L., Wu P.L., et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006, 60(6):645-649.
71. Yang C.R., Svensson K.A. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008, 120(3):317-332.
72. Javitt D.C., Cienfuegos A., Miniati M., et al. A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. J Clin Psychiatry 2002, 63(7):585-590.
73. Wilhelm S., Buhlmann U., Tolin D.F., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008, 165(3):335-341. quiz 409.
74. Kushner M.G., Kim S.W., Donahue C., et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007, 62(8):835-838.
75. de Bartolomeis A., Fiore G., Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005, 11(27):3561-3594.
76. Oliet S.H., Mothet J.P. Regulation of N-methyl-d-aspartate receptors by astrocytic D-serine. Neuroscience 2009, 158(1):275-283.
77. Morita Y., Ujike H., Tanaka Y., et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry 2007, 61(10):1200-1203.
78. Scolari M.J., Acosta G.B. D-serine: a new word in the glutamatergic neuro-glial language. Amino Acids 2007.
79. Billard J.M. D-serine signalling as a prominent determinant of neuronal-glial dialogue in the healthy and diseased brain. J Cell Mol Med 2008, 12(5B):1872-1884.
80. Gong X.Q., Zabek R.L., Bai D. d-Serine inhibits AMPA receptor-mediated current in rat hippocampal neurons. Can J Physiol Pharmacol 2007, 85(5):546-555.
81. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998, 44(11):1081-1089.
82. Heresco-Levy U., Javitt D.C., Ebstein R., et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005, 57(6):577-585.
83. Stip E., Trudeau L.E. Glycine and D-serine improve the negative symptoms of schizophrenia. Evid Based Ment Health 2005, 8(3):82.